Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENTA Enanta Pharmaceuticals	$4.73 -6.3%	$6.39	$4.52 ▼ $17.24	$100.91M	0.47	278,715 shs	397,323 shs
ETTX Entasis Therapeutics		$2.19	$1.40 ▼ $3.88	$104.80M	1.33	239,104 shs	800 shs
RNAC Cartesian Therapeutics	$10.00 -19.0%	$17.32	$9.12 ▼ $41.87	$259.07M	0.55	116,811 shs	340,911 shs
SCYX SCYNEXIS	$0.84 -6.7%	$1.03	$0.82 ▼ $3.07	$32.74M	1.67	184,019 shs	202,364 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENTA Enanta Pharmaceuticals	0.00%	-17.16%	-34.12%	-15.23%	-71.69%
ETTX Entasis Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
RNAC Cartesian Therapeutics	0.00%	-31.22%	-43.98%	-40.65%	-31.99%
SCYX SCYNEXIS	0.00%	-16.00%	-12.50%	-40.43%	-53.33%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENTA Enanta Pharmaceuticals	4.055 of 5 stars	3.4	1.0	0.0	4.7	2.4	4.2	0.6
ETTX Entasis Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	2.0456 of 5 stars	3.4	1.0	0.0	0.0	2.3	4.2	0.0
SCYX SCYNEXIS	0.5817 of 5 stars	0.0	5.0	0.0	0.0	0.0	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENTA Enanta Pharmaceuticals	2.80	Moderate Buy	$17.25	264.69% Upside
ETTX Entasis Therapeutics	0.00	N/A	N/A	N/A
RNAC Cartesian Therapeutics	2.80	Moderate Buy	$42.14	321.43% Upside
SCYX SCYNEXIS	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SCYX, ETTX, ENTA, and RNAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/14/2025	RNAC Cartesian Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$45.00 ➝ $40.00
3/13/2025	RNAC Cartesian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00 ➝ $41.00
2/11/2025	ENTA Enanta Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00 ➝ $21.00
2/11/2025	ENTA Enanta Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
1/28/2025	RNAC Cartesian Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $45.00
1/27/2025	RNAC Cartesian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00 ➝ $41.00
1/13/2025	RNAC Cartesian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00 ➝ $41.00

(Data available from 4/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENTA Enanta Pharmaceuticals	$66.59M	1.52	N/A	N/A	$5.24 per share	0.90
ETTX Entasis Therapeutics	$7M	0.00	N/A	N/A	$0.66 per share	0.00
RNAC Cartesian Therapeutics	$38.91M	6.66	N/A	N/A	($82.38) per share	-0.12
SCYX SCYNEXIS	$3.75M	8.74	$1.45 per share	0.58	$1.96 per share	0.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENTA Enanta Pharmaceuticals	-$116.04M	-$4.95	N/A	N/A	N/A	-157.57%	-75.53%	-27.30%	5/5/2025 (Estimated)
ETTX Entasis Therapeutics	-$47.14M	-$1.12	N/A	N/A	N/A	N/A	-145.48%	-103.75%	N/A
RNAC Cartesian Therapeutics	-$219.71M	-$52.83	N/A	N/A	N/A	-510.72%	N/A	-6.03%	5/6/2025 (Estimated)
SCYX SCYNEXIS	$67.04M	-$0.44	N/A	16.80	N/A	-425.41%	-66.21%	-38.84%	5/6/2025 (Estimated)

Latest SCYX, ETTX, ENTA, and RNAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/12/2025	Q4 2024	SCYX SCYNEXIS	-$0.22	-$0.09	+$0.13	-$0.09	N/A	$0.98 million
2/10/2025	Q1 2025	ENTA Enanta Pharmaceuticals	-$1.16	-$1.05	+$0.11	-$1.05	$17.25 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ETTX Entasis Therapeutics	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A
SCYX SCYNEXIS	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENTA Enanta Pharmaceuticals	N/A	5.47	5.47
ETTX Entasis Therapeutics	N/A	1.65	1.65
RNAC Cartesian Therapeutics	N/A	10.70	10.70
SCYX SCYNEXIS	N/A	3.13	3.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENTA Enanta Pharmaceuticals	94.99%
ETTX Entasis Therapeutics	6.91%
RNAC Cartesian Therapeutics	86.95%
SCYX SCYNEXIS	54.37%

Insider Ownership

Company	Insider Ownership
ENTA Enanta Pharmaceuticals	13.89%
ETTX Entasis Therapeutics	6.50%
RNAC Cartesian Therapeutics	57.90%
SCYX SCYNEXIS	2.85%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENTA Enanta Pharmaceuticals	160	21.33 million	18.37 million	Optionable
ETTX Entasis Therapeutics	51	47.85 million	44.74 million	Not Optionable
RNAC Cartesian Therapeutics	64	25.91 million	10.70 million	Optionable
SCYX SCYNEXIS	60	38.98 million	36.87 million	Optionable

SCYX, ETTX, ENTA, and RNAC Headlines

Recent News About These Companies

SCYNEXIS Full Year 2024 Earnings: Misses Expectations

March 14, 2025 | finance.yahoo.com

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

March 12, 2025 | markets.businessinsider.com

SCYNEXIS, Inc. Advances Phase 1 Trial of SCY-247 Antifungal and Prepares for Phase 3 MARIO Study Restart

March 12, 2025 | quiverquant.com

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

March 12, 2025 | globenewswire.com

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

December 18, 2024 | markets.businessinsider.com

Maxim Group Keeps Their Buy Rating on SCYNEXIS (SCYX)

December 5, 2024 | markets.businessinsider.com

SCYNEXIS’s Strong Financial Position and Strategic Advancements Drive Buy Rating

November 9, 2024 | markets.businessinsider.com

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 6, 2024 | globenewswire.com

Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years

October 30, 2024 | finance.yahoo.com

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

October 10, 2024 | globenewswire.com

Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc

October 7, 2024 | finance.yahoo.com

SCYNEXIS (NASDAQ:SCYX) Stock Quotes, Forecast and News Summary

October 4, 2024 | benzinga.com

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

October 3, 2024 | globenewswire.com

SCYNEXIS, Inc. (NASDAQ:SCYX) CEO Gonzalez David Angulo Acquires 20,000 Shares

September 17, 2024 | insidertrades.com

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

August 27, 2024 | globenewswire.com

Buy Rating Affirmed for SCYNEXIS Amid Antifungal Progress and Market Potential

August 13, 2024 | markets.businessinsider.com

SCYNEXIS, Inc. (SCYX) stock historical prices & data – Yahoo Finance

August 9, 2024 | au.finance.yahoo.com

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

August 9, 2024 | markets.businessinsider.com

SCYX Stock Earnings: SCYNEXIS Misses EPS, Misses Revenue for Q2 2024

August 9, 2024 | investorplace.com

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

August 8, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Word-of-Mouth Winners: 2 Stocks Growing Without Big Ad Budgets
By Leo Miller | March 21, 2025
View Word-of-Mouth Winners: 2 Stocks Growing Without Big Ad Budgets
Intel Stock Surges on New CEO – The Real Story Runs Deeper
By Gabriel Osorio-Mazilli | March 13, 2025
View Intel Stock Surges on New CEO – The Real Story Runs Deeper
3 Dividend Stocks Offering Higher Yields and Bullish Forecasts
By Sarah Horvath | March 17, 2025
View 3 Dividend Stocks Offering Higher Yields and Bullish Forecasts
Institutional Investors Bet $1B on These 4 Stocks—Should You?
By Sarah Horvath | March 9, 2025
View Institutional Investors Bet $1B on These 4 Stocks—Should You?
Can SoundHound AI Double? What the Fundamentals and Deals Reveal
By Gabriel Osorio-Mazilli | March 25, 2025
View Can SoundHound AI Double? What the Fundamentals and Deals Reveal

SCYX, ETTX, ENTA, and RNAC Company Descriptions

Enanta Pharmaceuticals NASDAQ:ENTA

$4.73 -0.32 (-6.34%)

Closing price 04/4/2025 04:00 PM Eastern

Extended Trading

$4.77 +0.04 (+0.93%)

As of 04/4/2025 07:25 PM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Entasis Therapeutics NASDAQ:ETTX

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.

Cartesian Therapeutics NASDAQ:RNAC

$10.00 -2.34 (-18.96%)

Closing price 04/4/2025 04:00 PM Eastern

Extended Trading

$9.95 -0.05 (-0.50%)

As of 04/4/2025 04:44 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

SCYNEXIS NASDAQ:SCYX

$0.84 -0.06 (-6.73%)

Closing price 04/4/2025 04:00 PM Eastern

Extended Trading

$0.84 0.00 (-0.12%)

As of 04/4/2025 04:05 PM Eastern

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time